Massachusetts Financial Services Co. MA Purchases 14,871 Shares of Sanofi (NASDAQ:SNY)

Massachusetts Financial Services Co. MA raised its position in shares of Sanofi (NASDAQ:SNYFree Report) by 14.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,609 shares of the company’s stock after acquiring an additional 14,871 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Sanofi were worth $6,148,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in shares of Sanofi by 2.5% in the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock worth $546,804,000 after purchasing an additional 249,619 shares during the last quarter. Morgan Stanley grew its holdings in shares of Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after purchasing an additional 1,251,199 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Sanofi by 20.4% in the second quarter. Bank of New York Mellon Corp now owns 7,556,281 shares of the company’s stock worth $407,284,000 after purchasing an additional 1,282,350 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Sanofi by 2.3% in the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Sanofi by 276.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. 10.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research analyst reports. Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Stifel Nicolaus cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Monday, October 30th. JPMorgan Chase & Co. cut shares of Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th. Finally, StockNews.com upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of “Hold” and an average price target of $57.50.

Read Our Latest Stock Analysis on SNY

Sanofi Stock Performance

SNY stock opened at $46.50 on Monday. The firm has a market cap of $117.63 billion, a price-to-earnings ratio of 19.70, a PEG ratio of 1.70 and a beta of 0.63. The firm has a 50-day simple moving average of $49.26 and a two-hundred day simple moving average of $50.60. Sanofi has a one year low of $42.63 and a one year high of $57.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.38 and a current ratio of 1.28.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.